

# A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention

Published: 21-09-2006

Last updated: 10-05-2024

The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Myocardial disorders
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON30625

### Source

ToetsingOnline

### Brief title

Champion Platform

### Condition

- Myocardial disorders

### Synonym

Acute coronary syndrome, Heart diseases

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Quintiles

**Source(s) of monetary or material Support:** The Medicines Company; 8 Campus Drive; Parsippany; USA

## Intervention

**Keyword:** Cangrelor, clopidogrel, Percutaneous coronary intervention (PCI), platelet inhibition

## Outcome measures

### Primary outcome

Primary endpoint:

The primary efficacy endpoint is a composite incidence of all-cause mortality,

MI, and IDR assessed

48 hours after randomization.

### Secondary outcome

Secondary endpoints:

- Incidence of :
  - all-cause mortality and MI at 48 hours
  - all-cause mortality and MI at 30 days
  - all-cause mortality, MI and IDR at 30 days
- Individual incidence of components of the composite (all-cause mortality, MI, and IDR)  
at 48 hours and 30 days
- Incidence of stroke, distinguished by type, at 48 hours
- Incidence of abrupt closure, threatened abrupt closure, need for urgent coronary artery bypass graft

(CABG) surgery, or unsuccessful procedure during the index PCI

- Incidence of all-cause mortality at 6 months (ascertained at the 1 year follow-up) and 1 year

## Study description

### Background summary

Each year, over one million patients undergo diagnostic coronary angiography and are discovered to have flow-limiting atherosclerotic plaques that may be amenable to PCI. Complications of PCI, and coronary stenting in particular, are well characterized and include death, myocardial infarction (MI), and the need for emergent or urgent repeat revascularization. A number of pre-procedural treatment strategies using anti-thrombotic therapies have evolved in an attempt to lower the rate of complications related to performance of PCI. Clopidogrel has become the accepted thienopyridine for clinical use in the post-stent setting because of its more favorable side effect profile. It is clear that usual care for patients undergoing PCI incorporates clopidogrel therapy based on convincing data revealing improved clinical outcomes when treatment is instituted immediately after PCI. However, there is ongoing debate about the optimal timing of clopidogrel administration, and the appropriate loading dose, given some suggestive but incomplete data on the benefits of pre-treatment. Clopidogrel is a prodrug and must be metabolized by the liver in order to generate the active metabolite. As a result there is a considerable delay in achieving platelet inhibition following oral administration. Furthermore, the binding of the active metabolite is irreversible, and new platelets must be generated in order to reverse the drug's effect. The potential benefits of Cangrelor in comparison to Clopidogrel before, and during the PCI procedure are the following: Cangrelor works directly after infusion, because the drug is not metabolized in the liver, the effect is reversible, and it works in 100% of the patient population.

### Study objective

The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality, myocardial infarction (MI), and ischemia

driven revascularisation.

## Study design

This is a multicentre phase 3, prospective, randomized, double-blind, placebo-controlled, with parallel groups.

## Intervention

De patients receive a 2 hour infusion Cangrelor 30 µg/kg intravenous (IV) bolus + 4 µg/kg/minute IV infusion, or placebo IV bolus and infusion, followed by the standard treatment with Clopidogrel (600mg directly after PCI/infusion followed by 1 year Clopidogrel 75 mg/dag

## Study burden and risks

The most common side effects reported to date include:

- hematoma (a collection of blood in the tissues) bruising
- bruising at the infusion puncture site
- stomach discomfort
- back pain
- chest pain

As a medication that affects the function of blood platelets, bleeding can occur at or into any place in the body including:

- into the urine
- at the site of needle sticks
- in the respiratory system

Bleeding events may be severe and result in other complications that may be long term, including death.

## Contacts

### Public

Quintiles

Siriusdreef 10  
2132 WT Hoofddorp  
Nederland

### Scientific

Quintiles

Siriusdreef 10  
2132 WT Hoofddorp

Nederland

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

Diagnostic coronary angiography demonstrating atherosclerosis (excluding ST segment-elevation) amenable to treatment by PCI with or without stent implantation

### Exclusion criteria

ST- Elevated MI patients who undergo PCI

## Study design

### Design

Study phase:	3
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

## Recruitment

NL  
Recruitment status: Recruitment stopped  
Start date (anticipated): 12-01-2007  
Enrollment: 100  
Type: Actual

## Medical products/devices used

Product type: Medicine  
Brand name: Cangrelor  
Generic name: NvT

## Ethics review

Approved WMO  
Date: 21-09-2006  
Application type: First submission  
Review commission: METC Noord-Holland (Alkmaar)

Approved WMO  
Date: 24-11-2006  
Application type: First submission  
Review commission: METC Noord-Holland (Alkmaar)

Approved WMO  
Date: 19-06-2007  
Application type: Amendment  
Review commission: METC Noord-Holland (Alkmaar)

Approved WMO  
Date: 06-09-2007  
Application type: Amendment  
Review commission: METC Noord-Holland (Alkmaar)

Approved WMO  
Date: 02-10-2007  
Application type: Amendment  
Review commission: METC Noord-Holland (Alkmaar)

Approved WMO

Date:	18-10-2007
Application type:	Amendment
Review commission:	METC Noord-Holland (Alkmaar)
Approved WMO	
Date:	13-03-2008
Application type:	Amendment
Review commission:	METC Noord-Holland (Alkmaar)
Approved WMO	
Date:	10-06-2008
Application type:	Amendment
Review commission:	METC Noord-Holland (Alkmaar)
Approved WMO	
Date:	07-04-2009
Application type:	Amendment
Review commission:	METC Noord-Holland (Alkmaar)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
EudraCT	EUCTR2006-003935-56-NL
CCMO	NL13979.094.06